Due to the ongoing global pandemic Covid-19, ESO and ESMO have taken the decision to convert the 9th ESO-ESMO Arab and Southern European Countries Masterclass in Clinical Oncology that was scheduled in 3-8 February 2021, into virtual ON-LINE MASTERCLASSES.
We have done our best to design and build a new programme keeping the interactive, international, and collaborative Masterclass spirit which will include prerecorded lectures, live sessions, clinical case presentations and direct contact with the Faculty members.
Programme, dates and further info will be available soon.
The online edition will be divided into two parts:
Pre-recorded lectures will be organized into Modules based on tumour type and made available for participants to view in their own time one month before part 2. On completion of each module, participants will be given the opportunity to send questions related to the lectures, that will then be answered Live by the Faculty during part 2.
All modules from part 1 must be completed before part 2.
Online live event with lectures/ live discussion and participants’ case presentations.
MCO Coordinator: N. Pavlidis, GR
ESO Chair: A. Eniu, CH
ESMO Chair: D. Papamichael, CY
Host Chair: A. Constantinidou, CY
Advisor: H. Khaled, EG
AIMS AND OBJECTIVES
This clinically oriented educational programme has been designed for medical and clinical oncologists who wish to improve their skills in the management of cancer patients.
The programme will expose participants to a full spectrum of issues in clinical oncology and to practice-orientated training. The programme focuses on breast, gynaecological, lung, urological and gastrointestinal cancers. Spotlight sessions will facilitate compact update on different topics related to cancer care.
Spotlight sessions will facilitate compact update on different topics related to cancer care.
The Masterclass offers plenary lectures discussing current issues and controversies as well as critically reviewing significant therapeutic developments. State-of-the-art data recognized by ESMO and other evidence-based guidelines will be cited. Participants will deliver case presentations within tumour boards and discuss them with the chairs and the faculty.
Participation is compulsory throughout the course. The Masterclass will be entirely in English and at least an intermediate level of English is necessary for admission.
• Full immersion
• An international faculty of top experts delivering lectures focusing on breast, gynaecological, lung, urological and
• Lung Cancer
• Gastrointestinal Cancer
• Breast Cancer
• Gynaecological Cancer
The Masterclass in
The complete list of invited speakers will soon be updated.
European School of Oncology - Bellinzona Office
Piazza Indipendenza 2
CH 6500 Bellinzona - Switzerland
Tel: +41 91 820 0952
Fax: +41 91 820 0953
Ph: +39 02 85464529
Application for CME recognition will be submitted to the European Society for Medical Oncology (ESMO) for ESMO-MORA accreditation, to the Accreditation Council of Oncology in Europe (ACOE), The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME)
Being selected to take part in an ESO Masterclass is one of the ESO activities that gives participants eligibility to enrol in ESCO - the College of the European School of Oncology.
A Masterclass also enables ESCO students to earn ESCO credits and therefore access more ESCO benefits. Full and active participation in the Masterclass earns participants 30 ESCO credits.
Visit www.esco.org for information on how to join ESCO.
IDEAL MASTERCLASS CANDIDATE
• Age below 40 years
• At least 2-3 years’ experience in medical or clinical oncology
• Involvement in scientific activities (preferable)
• Intermediate level of English
ATTENDANCE TO THE MASTERCLASS IS BY APPLICATION ONLY
Successful applicants are granted free registration and accommodation
THE APPLICATION DEADLINE HAS PASSED (8 November 2020)
The ONLINE 9th ESO-ESMO Arab and Southern European Countries Masterclass in Clinical Oncology will be divided into 2 parts:
Pre-recorded lectures will be made available to selected participants from 10th March 2021
Part 1 will be divided into 6 blocks, one for each tumour type and one including topics of general interest. Each block can be viewed in your own time, but all blocks must be viewed before Part 2.
A full detailed programme of Part 1 can be found below.
All participants will be asked to send up to 3 questions, each related to a big killer: the questions will be answered during part 2.
PART 2: (Dates: 10-11 April)
Online live event with lectures on latest updates or specifically related to the region, live discussions (Q&A) and participants’ case presentations in tumour boards.
Details of Part 2 will soon be published.
Part 1 Programme:
Part 1 has 6 blocks:
Block 1) Breast cancer
- Current controversies and challenges in breast cancer surgery – MJ Cardoso, PT
- Systemic treatment of early and advanced triple negative disease – G. Curigliano, IT
- Systemic treatment of HER2+ early and advanced disease – A. Eniu, CH
- Current controversies and challenges in radiotherapy – F. Geara, LB
- Preoperative chemotherapy and biologicals – N. Harbeck, DE
- Systemic treatment of luminal early and advanced breast cancer – O. Pagani, CH
- Molecular diagnostic pathology – G. Pruneri, IT
- Optimal approach in locally advanced disease: ESO-ESMO ABC Guidelines – F. Cardoso, PT
Block 2) Lung cancer
- Multimodality treatment of stage III NSCLC – R. Dziadziuszko, PL
- Molecular diagnostic pathology of NSCLC – I. Kern, SI
- Radiotherapy for NSCLC – F. Mc Donald, UK
- Systemic therapy for NSCLC with oncogenic driver mutations – C. Rolfo, US
- Systemic therapy for NSCLC without oncogenic driver mutations – S. Peters, CH
- Multimodality treatment of SCLC – R. Stahel, CH
- Surgery for early and locally advanced NSCLC – I. Schmitt-Opitz, CH
Block 3) Gastro-intestinal cancer
- Multimodal management of localized rectal cancer – A. Cervantes, ES
- Management of pancreatic cancer – S. De Dosso, CH
- Systemic treatment in advanced oesophageal and gastric cancer – F. Lordick, DE
- Adjuvant treatment in colon cancer – D. Papamichael, CY
- Liquid biopsies in GI tumors – F. Penault-Llorca, FR
- Optimal sequencing of systemic treatment for advanced hepatocellular carcinoma – A. Vogel, DE
- Systemic treatment in advanced colorectal cancer – E. van Cutsem, BE
Block 4) Gynaecological cancer
- Management of endometrial/cervical cancers – C. Sessa, CH
- Systemic management of ovarian cancer and inhibitors of Parp – J.B. Vermorken, BE
- New ESMO guidelines in Endometrial cancer – N. Colombo, IT
Block 5) Genitourinary cancer
- Management of testicular cancer – J. Beyer, CH
- First line endocrine therapy in endocrine sensitive prostate cancer – K. Fizazi, FR
- Localized prostate cancer – J. Khader, JO
- Systemic treatment of bladder cancer – H. Khaled, EG
- Treatment of endocrine resistant and refractory prostate cancer – X. Maldonado, ES
- Metastatic renal cancer: evidence-based treatment – N. Mottet, FR
Block 6) Spotlights
- Communication skills – F. Boyle, AU
- Ethics issues – S. Hurst-Majno, CH
- Breast cancer during pregnancy and fertility preservation – F.A. Peccatori, IT
- Early integration in oncology, supportive and palliative care – S. Peters, CH
- Cancer patients with COVID-19 – M. Garassino, IT
- Nutrition – J. Arends, DE
- Genomic Tests in clinical practice – F. Cardoso, PT
- Cancer in the elderly – M. Aapro, CH
- Immuno-oncology – H.A. Azim Jr., MX